RxDoctor Payments Data

Jessica Waddell, NP

Family · Norfolk, VANPI 1861739377

Payments from drug & device makers

$1,886in general payments, 2019–2025

Across 22 payments — averaging $85.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Novo Nordisk$125
  • Lundbeck LLC$125
  • Amgen$125
  • Esperion Therapeutics, Inc.$90
  • AbbVie$84
  • plus $238 from 4 others

What the payments were for

  • Travel & lodging$87046%
  • Food & beverage$97852%
  • Education$382%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,886 in reported general payments places this provider in the 80th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$17,901
Medicare patients
179
Services billed
283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban155$161,014
EntrestoSacubitril/Valsartan28$38,880
XareltoRivaroxaban24$37,674
Repatha SureclickEvolocumab37$27,549
BrilintaTicagrelor12$13,602
Metoprolol Succinate165$2,123
Atorvastatin Calcium124$1,474
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$1,308
Ranolazine ErRanolazine21$1,110
Nebivolol Hcl15$979
Spironolactone76$886
Isosorbide Mononitrate ErIsosorbide Mononitrate60$818
Carvedilol103$733
Rosuvastatin Calcium47$705
ClopidogrelClopidogrel Bisulfate75$692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$77$38,88028 claims
Johnson & JohnsonXarelto$38$37,67424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,332 family providers in Virginia.

Other family in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →